Clinitech Laboratory Ltd (CTLLAB) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Clinitech Laboratory Ltd on NSE and BSE, with an AI summary of each filing.
Undertaking of non-applicability of REgulation 23 of SEBI (LODR) Regulations, 2015 w.r.t Related Party Transcations
Transcript · 22 Oct 2026, 11:57 pm
Clinitech Laboratory Reports RPT Disclosure Exemption Under SEBI LODR Regulations Clinitech Laboratory Limited confirmed that Related Party Transaction disclosures under Regulation 23 of SEBI LODR Regulations, 2015 are not applicable for the half year ended 30th Sep'26. As a BSE SME-listed entity, the company remains exempt under Regulation 15. A Practicing Company Secretary certificate verified that paid-up equity capital stood at Rs 2.28 crore for FY26 and FY25 (Rs 1.68 crore in FY24), while net worth reached Rs 9.25 crore in FY26, up from Rs 8.83 crore in FY25 and Rs 3.55 crore in FY24.
Voting Results and Scrutinizers Report for voting of AGM held on September 24, 2026 at 11.30 AM through video conferencing
Annual General Meeting · 25 Sept 2026, 12:21 am
Proceedings of 16th Annual General Meeting held today i.e September 24, 2026 at 11.30 AM through video conferencing
Annual General Meeting · 25 Sept 2026, 12:07 am
Notice of Annual General Meeting along with all annexures to be held on September 24, 2026 at 11.30 A.M (IST) through video conferencing.
Annual General Meeting · 22 Aug 2026, 11:20 pm
Annual Report for thr FY 2025-26 along with Notice of AGM and all annexures thereto
Others (Uncategorized) · 22 Aug 2026, 10:56 pm
We hereby inform that the Board of Directors of the company, at its meeting held today i.e., August 17, 2026, for which intimation was already given, have: Approved appointment of director ....
Outcome · 17 Aug 2026, 5:41 pm
Clinitech Laboratory Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 17/08/2026 ,inter alia, to consider and approve 1. To consider and approve ....
Intimation · 12 Aug 2026, 7:00 pm
Statement disclosing no deviation and Variation from object of issue as on March 31, 2026
Others (Uncategorized) · 28 May 2026, 10:29 pm
Clinitech Laboratory Reports No Deviation in IPO Fund Utilization for Quarter Ended Mar'26 Clinitech Laboratory Limited reported no deviation or variation in the use of IPO funds for the quarter ended 31st Mar'26. From the total INR 578.30 lakhs raised via its public issue on 30th Jul'24, the company has utilized INR 528.30 lakhs, or approximately 91.5% of the proceeds. The utilized funds were allocated as intended in the prospectus: INR 448.67 lakhs for diagnostic centre expansion and INR 41.33 lakhs for general corporate purposes, with the remainder for issue-related expenses, leaving no unutilized balance for these core objectives.
Outcome of Board meeting held today i.e May 28, 2026 through video conferencing at 02.30 P.M for approval of Audited Financial Results for the half year and financial year ended March 31, 2026
Financial Result · 28 May 2026, 8:42 pm
Clinitech Laboratory Reports FY26 Results and Approves Related Party Transactions Clinitech Laboratory's board approved audited standalone and consolidated financial results for the half and full year ended 31 Mar'26. For FY26 (standalone), revenue from operations grew 15.1% YoY to ₹947.50 lakh, while profit after tax rose 7.0% YoY to ₹42.25 lakh. The auditor issued an unmodified opinion. The board also approved estimated related party transactions for FY27. Out of ₹578.30 lakh IPO proceeds, ₹528.30 lakh has been utilized as of 31 Mar'26, with the remaining ₹50.00 lakh held in deposits.
With reference to the above captioned subject, we wish to intimate your esteemed exchange that as decided in the Meeting of the Board of Directors of the Company held today, i.e., on May, ....
Outcome · 28 May 2026, 8:30 pm
Clinitech Laboratory Ltd - Financial Result for the Quarter ended 31st Mar'26 (Consolidated, INR Lakh) ■ Revenue: 441 (+6.1% YoY | -13.2% QoQ) ■ EBITDA: 44.9 (+62.2% YoY | -16.6% QoQ) ■ EBITDA Margin (%): 10.2 (+352 bps YoY | -42 bps QoQ) ■ PAT: 11.8 (-32.2% YoY | -60.8% QoQ) ■ EPS (INR): 0.52 (-37.3% YoY | -60.6% QoQ)
Clinitech Laboratory Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/05/2026 ,inter alia, to consider and approve To consider and approve ....
Intimation · 28 May 2026, 5:30 am
Clinitech Laboratory Board Meeting on May 28 to Approve FY26 Financials Clinitech Laboratory Limited (BSE: 544220) will hold a Board of Directors meeting on 28 May'26 at 02:30 PM IST. The key agenda is to consider and approve the Audited Standalone and Consolidated Financial Results for the half-year and financial year ended 31 Mar'26. The board will also review the internal audit report and related party transactions. The trading window for designated persons has been closed from 01 Apr'26 and will reopen 48 hours after the results are announced on 28 May'26.
<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=''1px''><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> ....
Others (Uncategorized) · 27 Apr 2026, 5:02 pm
Clinitech Laboratory Confirms It Is Not Classified as a Large Corporate On Apr 22, '26, Clinitech Laboratory Limited informed the BSE it does not meet the criteria for a Large Corporate (LC) under SEBI's Nov 2018 circular. A subsequent filing on Apr 27, '26 confirmed this, citing outstanding borrowings of just ₹0.36 cr as of Mar 31. The company also reported having no credit rating for the previous fiscal year. This status exempts Clinitech from the mandatory requirement to raise a portion of its incremental borrowings through debt securities.
This is to inform that the company has entered into Memorandum Of Understanding ("MOU") dated 25th April, 2026 with M/s. MD Plus Multispeciality Clinic
Others (Uncategorized) · 25 Apr 2026, 11:43 pm
Clinitech Laboratory Signs MOU with MD Plus Multispeciality Clinic Clinitech Laboratory Limited signed a Memorandum of Understanding (MOU) on 25th Apr'26 with M/s. MD Plus Multispeciality Clinic. Under the agreement, Clinitech will operate the pathology lab and manage pathology pickup points at the clinic. The company will also handle full referral radiology services. This partnership aims to expand Clinitech's operational footprint and service offerings through a collaboration with a multispeciality clinic, potentially increasing patient volume and revenue streams from both pathology and radiology segments.
Undertaking for non-applicability of disclosure under Reg 23 of SEBI (LODR) Regulations, 2015 w.r.t related party transaction.
Others (Uncategorized) · 22 Apr 2026, 6:58 pm
Clinitech Laboratory Claims Exemption from Related Party Transaction Disclosure Norms Clinitech Laboratory Limited (BSE: 544220) has informed the exchange on Apr 22, '26, that disclosure requirements for Related Party Transactions (RPT) under SEBI's Regulation 23 are not applicable for the half-year and financial year ended Mar 31, '26. The company stated its exemption is based on Regulation 15 of SEBI (LODR) Regulations, 2015, citing its listing on the SME portal of BSE and not exceeding specified threshold limits for such disclosures.
General update under Reg 30 of SEBI (LODR) Regulations for change in market maker from SVCM Securities Private Limited to Kalpalabdhi Financials Private Limited w.e.f April 10, 2026 as ....
Others (Uncategorized) · 09 Apr 2026, 9:14 pm
Clinitech Laboratory Announces Change in Market Maker Clinitech Laboratory Limited announced a change in its market maker from SVCM Securities Private Limited to Kalpalabdhi Financials Private Limited, effective 10 Apr'26. The Board of Directors approved this change via a circular resolution on 09 Apr'26. The transition follows the discontinuation of the market-making business by SVCM Securities due to internal restructuring. A tripartite agreement has been executed between Clinitech, the new market maker Kalpalabdhi Financials, and the Lead Manager, Inventure Merchant Banker Services.
General Update w.r.t to receipt of letter from promoter under Reg 31(4) of SEBI SAST regulations for the yera ended March 31, 2026
Others (Uncategorized) · 06 Apr 2026, 10:11 pm
Clinitech Laboratory: Promoter Group Confirms No Share Encumbrance in FY26 Clinitech Laboratory's Promoter and Promoter Group submitted its yearly disclosure under SEBI's SAST regulations for the year ended 31st Mar'26. The filing confirms no encumbrance was made over shares held by the promoter group during the fiscal year. Promoter Jagdish Umakant Nayak acquired an additional 9,600 equity shares on 30th Mar'26, which was reflected in the BENPOS on 1st Apr'26. This acquisition took his total holding from 722,500 shares as of 31st Mar'26, as per RTA data, to a higher figure post-transaction.
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Jagdish Nayak & PACs
Acquisition/ Disposal of Shares · 30 Mar 2026, 11:27 pm
Clinitech Laboratory Promoter Increases Stake Through Open Market Purchase Promoter and Managing Director of Clinitech Laboratory, Jagdish Umakant Nayak, acquired 9,600 equity shares via an open market transaction on 30 Mar'26. This purchase represents 0.42% of the company's total voting capital. Following the acquisition, the total holding of the promoter and persons acting in concert (PACs) increased from 14,65,400 shares (64.20%) to 14,75,000 shares (64.62%). The company's total equity share capital remains unchanged at 22,82,400 shares post-transaction.
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Siddhesh Nayak & PACs
Acquisition/ Disposal of Shares · 30 Mar 2026, 6:02 pm
Clinitech Laboratory Promoter Group Increases Stake via Open Market Purchase Clinitech Laboratory's promoter group member, Siddhesh Anant Nayak, acquired 2,400 equity shares via an open market transaction on 27 Mar'26. This purchase increased the total holding of the acquirer and Persons Acting in Concert (PACs) from 14,64,200 shares (64.15%) to 14,65,400 shares (64.20%). The company's total equity share capital remains unchanged at 22,82,400 shares. This disclosure was made under SEBI's substantial acquisition regulations.
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Jagdish Umakant Nayak & PACs
Acquisition/ Disposal of Shares · 28 Mar 2026, 10:12 pm
Promoter Group Increases Stake in Clinitech Laboratory via Open Market Purchase Promoter and Managing Director Jagdish Umakant Nayak, along with Persons Acting in Concert (PACs), acquired 1,200 equity shares of Clinitech Laboratory through an open market purchase on 25 Mar'26. This acquisition represents 0.05% of the company's total voting capital. Following the transaction, the promoter group's total holding increased from 1,463,000 shares (64.10%) to 1,464,200 shares (64.15%). The company's total equity share capital remained unchanged at 2,282,400 shares. This disclosure was made under SEBI's SAST Regulations, 2011.
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Siddhesh Anant Nayak & PACs
Acquisition/ Disposal of Shares · 27 Mar 2026, 5:26 pm
Clinitech Laboratory: Promoter Group Acquires Shares, Increases Stake Promoter group member Siddhesh Anant Nayak, along with Persons Acting in Concert (PACs), acquired 2,400 equity shares of Clinitech Laboratory (CTLLAB) via an open market transaction on 24 Mar'26. This purchase represents 0.11% of the total voting capital. Following the acquisition, the total holding of the acquirer and PACs increased from 14,60,600 shares (63.99%) to 14,63,000 shares (64.10%). The company's total equity share capital remains unchanged at 22,82,400 shares.
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Jagdish Umakant Nayak & PACs
Acquisition/ Disposal of Shares · 20 Mar 2026, 11:25 pm
Clinitech Laboratory Promoter Increases Stake Through Open Market Purchase Promoter & Managing Director Jagdish Umakant Nayak, along with Persons Acting in Concert (PACs), acquired 4,800 equity shares of Clinitech Laboratory Ltd (BSE: 544220) via open market transactions on 19-Mar'26 and 20-Mar'26. The purchase consisted of 2,400 shares on each day. This acquisition increased the total promoter group holding by 0.21%, from 63.78% (14,55,800 shares) to 63.99% (14,60,600 shares). The company's total equity share capital remains unchanged at 22,82,400 shares post-acquisition.
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Jagdish Umakant Nayak & PACs
Acquisition/ Disposal of Shares · 18 Mar 2026, 11:17 pm
Clinitech Laboratory Promoter Increases Stake Through Open Market Purchase Jagdish Umakant Nayak, Promoter & MD of Clinitech Laboratory, and associated PACs acquired 4,800 equity shares via open market transactions on 17-Mar'26 and 18-Mar'26. This purchase represents 0.21% of the company's total equity share capital. Post-acquisition, the promoter group's total holding increased from 14,51,000 shares (63.57%) to 14,55,800 shares (63.78%). The total voting capital of the company before and after the acquisition remained at 22,82,400 shares, as per the filing.
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Jagdish Umakant Nayak
Acquisition/ Disposal of Shares · 14 Mar 2026, 5:04 pm
Clinitech Laboratory Promoter Increases Stake Through Open Market Purchase Promoter and MD Jagdish Umakant Nayak acquired 6,000 shares of Clinitech Laboratory Ltd via open market transactions. A total of 2,400 shares were bought on 12 Mar’26, and 3,600 shares on 13 Mar’26. This acquisition increased the promoter's holding by 0.26% to 7,11,700 shares, representing 31.18% of the company's total voting capital. The transaction was disclosed under SEBI (SAST) Regulations, 2011. This move signals strengthening promoter confidence in the company.
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Jagdish Umakant Nayak
Acquisition/ Disposal of Shares · 12 Mar 2026, 7:50 pm
Clinitech Laboratory Promoter Increases Stake Through Open Market Purchase Jagdish Umakant Nayak, Promoter & Managing Director of Clinitech Laboratory Ltd, acquired 8,400 equity shares via an open market transaction on 11 Mar'26. This purchase represents 0.37% of the company's total voting capital. Following the acquisition, his total shareholding in the company increased from 6,97,300 shares (30.55%) to 7,05,700 shares (30.92%). The company's total equity share capital remains unchanged at 22,82,400 shares. This action signals increased promoter conviction in the company.
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Jagdish Umakant Nayak
Acquisition/ Disposal of Shares · 10 Mar 2026, 6:53 pm
Clinitech Promoter Increases Stake Through Open Market Purchase Jagdish Umakant Nayak, a promoter of Clinitech Laboratory Ltd (BSE: 544220), acquired 3,600 equity shares via an open market transaction on 10 Mar '26. This purchase increased his shareholding from 6,93,700 shares (30.39%) to 6,97,300 shares (30.55%). The transaction represents a 0.16% increase in his stake. The total voting capital of the company remains unchanged at 22,82,400 shares post-acquisition. This disclosure was made under SEBI's SAST Regulations, 2011, highlighting continued promoter confidence.